DepYmed to Present at the 9th World Rett Syndrome Congress
October 02, 2024 09:00 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many...
DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome
March 19, 2024 10:59 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., March 19, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many...
DepYmed to Meet with Investors at the BIO CEO and Investor Conference
February 21, 2024 09:35 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
February 07, 2024 09:45 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023
October 03, 2023 09:45 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Oct. 03, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed to Meet with Investors at the BioFuture Conference in New York City October 4-6, 2023
September 27, 2023 09:45 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
DepYmed to Meet with Investors at the LSX World Congress USA in Boston on September 13-14, 2023
September 08, 2023 09:45 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
June 15, 2023 09:00 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
May 31, 2023 09:30 ET
|
DepYmed, Inc.
FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
November 16, 2022 09:35 ET
|
DepYmed, Inc.
FARMINGDALE, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...